BIOVECTRA Increases Manufacturing Services


New microbial fermentation tech expected to boost CDMO’s overall capacity

BIOVECTRA is now ready to accept projects at its manufacturing facility in Windsor, NS, Canada, for its new, single-use biologics fermentation suite. Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train enhances the contract development and manufacturing organization (CDMO)’s microbial fermentation overall capacity. It also allows the company to support even more promising biologics for their tech-transfer and optimization, early and mid-stage clinical investigation, along with commercial scale supply of highly specialized therapeutics.

The addition of single-use fermentation capability provides BIOVECTRA customers with several benefits, such as more flexibility, faster turnaround times, and increased capacity utilization. Additional advantages include a decreased risk of contamination, and the elimination of costly and time-consuming cleaning and sterilization between batches.

“Our closed, sterile single-use fermenters are designed to provide mixing, oxygen transfer, and cooling capabilities comparable to stainless-steel bioreactors, while being more agile and avoiding their fixed costs, which is a benefit many of our clients are eager to explore,” comments Heather Delage, BIOVECTRA’s chief commercial officer. “ … Companies that want to start a clinical program and take it to commercial launch are no longer faced with an either/or choice of single-use versus stainless-steel fermenters,” Delage continues. “The combination of the two can be ideal for those engaged in clinical-to-commercial scale production.”

Read more about the CDMO’s expansion of services here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.